These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37391394)

  • 21. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
    Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
    Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
    Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM
    Front Immunol; 2021; 12():742914. PubMed ID: 34659237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment.
    Strobel SB; Machiraju D; Kälber KA; Hassel JC
    Cancer Immunol Immunother; 2022 Aug; 71(8):2051-2056. PubMed ID: 34940894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination.
    Sisteré-Oró M; Wortmann DDJ; Andrade N; Aguilar A; Mayo de Las Casas C; Casabal FG; Torres S; Bona Salinas E; Raventos Soler L; Arcas A; Esparre C; Garcia B; Valarezo J; Rosell R; Güerri-Fernandez R; Gonzalez-Cao M; Meyerhans A
    Front Immunol; 2022; 13():908108. PubMed ID: 35911701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of COVID-19 mRNA Vaccination in Patients Treated With Clozapine WHO Previously Went Through SARS-COV-2 Infection.
    Moga S; Petric PS; Miron AA; Ifteni P; Teodorescu A
    Am J Ther; 2023 May; 30(3):e186-e196. PubMed ID: 37097999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of anti-SARS-CoV-2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient-reported outcome study.
    Harada D; Tamura T; Ninomiya K; Kubo T; Kuyama S; Tachibana S; Inoue K; Chikamori K; Kudo K; Ochi N; Maeda Y; Kiura K
    Thorac Cancer; 2023 Jan; 14(3):231-236. PubMed ID: 36404396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of COVID-19 vaccines in lung cancer patients.
    Provencio M; Estival A; Franco F; López-Vivanco G; Saigí M; Arasanz H; Diz P; Carcereny E; García J; Aguado C; Mosquera J; Iruarrizaga E; Majem M; Bosch-Barrera J; Mielgo-Rubio X; Guirado M; Juan-Vidal Ó; Blasco A; Lucía Gozálvez C; Del Barrio A; De Portugal T; López-Martín A; Serrano G; Campos B; Rubio J; Catot S; Esteban B; Martí-Ciriquian JL; Del Barco E; Calvo V;
    Lung Cancer; 2023 Oct; 184():107323. PubMed ID: 37639820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis.
    Isgrò MA; Vitale MG; Celentano E; Nocerino F; Porciello G; Curvietto M; Mallardo D; Montagnese C; Russo L; Zanaletti N; Avallone A; Pensabene M; De Laurentiis M; Centonze S; Pignata S; Cannella L; Morabito A; Caponigro F; Botti G; Masucci GV; Giannarelli D; Cavalcanti E; Ascierto PA
    J Transl Med; 2021 Mar; 19(1):132. PubMed ID: 33789686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report.
    Dipasquale A; Persico P; Lorenzi E; Rahal D; Santoro A; Simonelli M
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33574054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
    Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
    Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries.
    Cortellini A; Dettorre GM; Dafni U; Aguilar-Company J; Castelo-Branco L; Lambertini M; Gennatas S; Angelis V; Sita-Lumsden A; Rogado J; Pedrazzoli P; Viñal D; Prat A; Rossi M; Berardi R; Alonso-Gordoa T; Grisanti S; Dimopoulou G; Queirolo P; Pradervand S; Bertuzzi A; Bower M; Arnold D; Salazar R; Tucci M; Harrington KJ; Mazzoni F; Mukherjee U; Tsourti Z; Michielin O; Pommeret F; Brunet J; Vincenzi B; Tonini G; Patriarca A; Biello F; Krengli M; Tabernero J; Pentheroudakis G; Gennari A; Peters S; Romano E; Pinato DJ
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks.
    Esmaeilzadeh A; Maleki AJ; Moradi A; Siahmansouri A; Yavari MJ; Karami P; Elahi R
    Expert Rev Vaccines; 2022 Oct; 21(10):1377-1394. PubMed ID: 35986451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak.
    Tagliamento M; Spagnolo F; Poggio F; Soldato D; Conte B; Ruelle T; Barisione E; De Maria A; Del Mastro L; Di Maio M; Lambertini M
    Eur J Clin Invest; 2020 Sep; 50(9):e13315. PubMed ID: 32535890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors.
    Terpos E; Zagouri F; Liontos M; Sklirou AD; Koutsoukos K; Markellos C; Briasoulis A; Papanagnou ED; Trougakos IP; Dimopoulos MA
    J Hematol Oncol; 2021 May; 14(1):86. PubMed ID: 34059088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
    Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
    Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD
    Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of SARS-CoV-2 mRNA-Vaccine on the Induction of Myocarditis in Different Murine Animal Models.
    Zirkenbach VA; Ignatz RM; Öttl R; Cehreli Z; Stroikova V; Kaya M; Lehmann LH; Preusch MR; Frey N; Kaya Z
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.